Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Lignende værker

• Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
  af: Ishikura, Nobuyuki, et al.
  Udgivet: (2019)
• Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
  af: Iwai, Toshiki, et al.
  Udgivet: (2016)
• Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
  af: Iwai, Toshiki, et al.
  Udgivet: (2018)
• MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells
  af: Nishidate, Masanobu, et al.
  Udgivet: (2017)
• Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
  af: Masuda, Chinami, et al.
  Udgivet: (2019)